Quarterly report pursuant to sections 13 or 15(d)

Statements of Cash Flows (Unaudited)

v2.3.0.11
Statements of Cash Flows (Unaudited) (USD $)
9 Months Ended 25 Months Ended
Sep. 30, 2011
Sep. 30, 2010
Sep. 30, 2011
Cash flows from operating activities:      
Net loss $ (541,322) $ (169,713) $ (927,438)
Adjustments to reconcile net loss to net cash used in operating activities:      
Amortization of intangible assets 48,215 0 58,929
Stock based compensation 129,414 0 129,536
Changes in:      
Inventory (8,015) 0 (7,794)
Prepaid expenses (67) 0 1,122
Accounts payable 170,371 8,307 216,648
Accrued expenses (80,756) 73,284 94,937
Net cash used in operating activities (281,800) (88,122) (434,060)
Cash flows from investing activities:      
Net cash acquired in acquisition of Boston Therapeutics, Inc. 0 0 8,397
Net cash provided by investing activities 0 0 8,397
Cash flows from financing activities      
Proceeds from advances - related party 80,000 73,505 197,820
Proceeds from investment in capital stock - related party 0 21,236 21,236
Proceeds from capital stock issued 522,977 0 522,997
Proceeds from investment in capital stock 0 0 20,000
Net cash provided by financing activities 602,997 94,741 762,053
Net increase (decrease) in cash and cash equivalents 321,197 6,619 336,390
Cash and cash equivalents, beginning of period 15,193 23,530  
Cash and cash equivalents, end of period 336,390 30,149 336,390
Acquisition of Boston Therapeutics, Inc.:      
Fair value of assets acquired     985,466
Assumed liabilities     $ (106,819)
Fair value of common stock issued     878,647